The vaccine primes neoantigen-specific CD8+ T cells that recognize tumor neoantigen peptides presented on HLA class I (e.g., HLA‑B) and kill those tumor cells via CTL-mediated lysis (perforin/granzyme, Fas/FasL). HLA‑B expression alone is not the cytotoxic target.